The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
Open accessAbstract
The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10–27%. New diagnostics reduce incidence by 13–42%. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71%. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30% more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37% and 82%, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94%. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes in C: the art of scientific computing
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933
Numerical Recipes in C-The Art of Scientific Computing.
G., W., Press, W. H., Flannery, B. P., Teukolsky, S. A., & Vetterling, W. T. (1989) · Mathematics of Computation · doi:10.2307/2008673 · Cited by 1,513
Small, P. M., Hopewell, P. C., Singh, S. P., Paz, A., Parsonnet, J., Ruston, D. C., Schecter, G. F., Daley, C. L., & Schoolnik, G. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406163302402 · Cited by 1,111
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Global tuberculosis control: surveillance planning financing. WHO report 2008.
Dye, C., Floyd, K., & Uplekar, M. (2008) · Cited by 575
Self-citationVYNNYCKY, E., & FINE, P. E. M. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007917 · Cited by 555
[Epidemiology of tuberculosis].
Neumann, G. (1971) · PubMed · Cited by 523
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Jindani, A., Aber, V. R., Edwards, E. A., & Mitchison, D. A. (1980) · PubMed · doi:10.1164/arrd.1980.121.6.939 · Cited by 487
The intrinsic transmission dynamics of tuberculosis epidemics
Blower, S. M., Mclean, A. R., Porco, T. C., Small, P. M., Hopewell, P. C., Sanchez, M. A., & Moss, A. R. (1995) · Nature Medicine · doi:10.1038/nm0895-815 · Cited by 471
Prospects for worldwide tuberculosis control under the WHO DOTS strategy
Dye, C., Garnett, G. P., Sleeman, K., & Williams, B. G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03199-7 · Cited by 462
Self-citationTuberculosis: Pathogenesis, protection, and control
De Cock, K. M. (1995) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(95)90122-1 · Cited by 417
Raviglione, M. C., & Uplekar, M. W. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68392-x · Cited by 398
Control Strategies for Tuberculosis Epidemics: New Models for Old Problems
Blower, S. M., Small, P. M., & Hopewell, P. C. (1996) · Science · doi:10.1126/science.273.5274.497 · Cited by 350
Study Designs for Evaluating Different Efficacy and Effectiveness Aspects of Vaccines
Halloran, M. E., Struchiner, C. J., & Longini, I. M. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009196 · Cited by 346
Self-citationLifetime Risks, Incubation Period, and Serial Interval of Tuberculosis
Vynnycky, E. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.3.247 · Cited by 322
Advances in tuberculosis vaccine strategies
Skeiky, Y. A. W., & Sadoff, J. C. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1419 · Cited by 299
Crossley, P. E. L. (1954) · International Journal of Dairy Technology · doi:10.1111/j.1471-0307.1954.tb00809.x · Cited by 259
Reducing the global burden of tuberculosis: the contribution of improved diagnostics
Keeler, E., Perkins, M. D., Small, P., Hanson, C., Reed, S., Cunningham, J., Aledort, J. E., Hillborne, L., Rafael, M. E., Girosi, F., et al. (2006) · Nature · doi:10.1038/nature05446 · Cited by 245
Self-citationModeling the impact of global tuberculosis control strategies
Murray, C. J. L., & Salomon, J. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13881 · Cited by 237
Sutherland, I. (1976) · PubMed · Cited by 210
New Tuberculosis Therapeutics: A Growing Pipeline
Spigelman, M. K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518663 · Cited by 169
Targets for global tuberculosis control.
Dye, C., Maher, D., Weil, D. E. C., et al. (2006) · PubMed · Cited by 155
Self-citationThe development of clinical tuberculosis following infection with tubercle bacilli
Sutherland, I., Svandova, E., & Radhakrishna, S. (1982) · Tubercle · doi:10.1016/s0041-3879(82)80013-5 · Cited by 144
Smith, P. G., & Moss, A. R. (2014) · Tuberculosis · doi:10.1128/9781555818357.ch4 · Cited by 142
Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis
Resch, S., Salomon, J. A., Murray, M. B., & Weinstein, M. C. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030241 · Cited by 112
Coberly, J. S., & Comstock, G. W. (2006) · CRC Press eBooks · doi:10.3109/9780203908464-10 · Cited by 104
[Epidemiology of tuberculosis].
Durieux, P. (1990) · PubMed · Cited by 103
Dowdy, D. W., Chaisson, R. E., Maartens, G., Corbett, E. L., & Dorman, S. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800965105 · Cited by 94
Prospects for Advancing Tuberculosis Control Efforts through Novel Therapies
Salomon, J. A., Lloyd‐Smith, J. O., Getz, W. M., Resch, S., Sánchez, M. S., Porco, T. C., & Borgdorff, M. W. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030273 · Cited by 93
Moulton, L. H., Golub, J. E., Durovni, B., Cavalcante, S. C., Pacheco, A. G., Saraceni, V., King, B., & Chaisson, R. E. (2007) · Clinical Trials · doi:10.1177/1740774507076937 · Cited by 82
[Epidemiology of tuberculosis].
Bermejo, M. A. M., Clavera, I., Michel de la Rosa, F., & Marín, B. (2007) · PubMed · Cited by 79
Comparing epidemic tuberculosis in demographically distinct heterogeneous populations
Murphy, B. M., Singer, B. H., Anderson, S. M., & Kirschner, D. E. (2002) · Mathematical Biosciences · doi:10.1016/s0025-5564(02)00133-5 · Cited by 73
On treatment of tuberculosis in heterogeneous populations
Murphy, B. M., Singer, B. H., & Kirschner, D. E. (2003) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(03)00038-9 · Cited by 60
The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901.
Vynnycky, E., & Fine, P. (1997) · PubMed · Cited by 56
Ammari, L., Berriche, A., Kooli, I., Marrakchi, W., & Chakroun, M. (2022) · Medical radiology · doi:10.1007/978-3-031-07040-2_1 · Cited by 27
Impact of HIV on novel therapies for tuberculosis control
Sánchez, M. S., Lloyd‐Smith, J. O., Porco, T. C., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb4b · Cited by 6
Cited by
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“As described by Abu-Raddad et al [241], improved detection of those with TB and improved identification of those at risk to progress once infected have the potential to substantially decrease the prevalence of TB and its associated mortality.”
MethodTuberculosis control and elimination 2010–50: cure, care, and social development
Lönnroth, K., Castro, K. G., Chakaya, J. M., Chauhan, L. S., Floyd, K., Glaziou, P., & Raviglione, M. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60483-7 · Cited by 899
The Population Dynamics and Control of Tuberculosis
Dye, C., & Williams, B. G. (2010) · Science · doi:10.1126/science.1185449 · Cited by 604
Self-citationRoy, A., Eisenhut, M., Harris, R. J., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L., Mangtani, P., Adetifa, I., Lalvani, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4643 · Cited by 588
Metadata
- Authors
- Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-08-18
- Volume
- 106
- Issue
- 33
- Pages
- 13980-13985
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2047509792
- Cited by
- 348
- References
- 37
- FWCI
- 16.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.